Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 1/20 | 0.45 |
| ▸ | GAA | P10253 | 1/20 | 0.45 |
| ▸ | KCNK3 | O14649 | 3/20 | 0.44 |
| ▸ | KCNK9 | Q9NPC2 | 3/20 | 0.44 |
| ▸ | PTGS1 | P23219 | 1/20 | 0.44 |
| ▸ | PTGES | O14684 | 5/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.41 |
| ▸ | RECQL | P46063 | 1/20 | 0.41 |
| ▸ | F2R | P25116 | 1/20 | 0.41 |
| ▸ | PTPRC | P08575 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17064212 | 0.92 | SMN1; SMN2 (0.46) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL17064204 | 0.88 | RXFP1 (0.40) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL17064201 | 0.85 | KCNK3 (0.44) | LMNAKCNK3KCNK9PTGESKMT2A | |
| SCHEMBL17064208 | 0.83 | KDR (0.45) | KMT2A | |
| SCHEMBL17064210 | 0.81 | PTGES (0.41) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL17073933 | 0.81 | KMT2A (0.44) | LMNAGAAKMT2ATP53RXFP1 | |
| SCHEMBL17073927 | 0.80 | MEN1 (0.44) | LMNAKCNK3KCNK9KMT2ARXFP1 | |
| SCHEMBL17111294 | 0.80 | STIM1 (0.51) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL17145113 | 0.77 | KCNK3 (0.50) | LMNAGAAKCNK3KCNK9PTGS1 | |
| SCHEMBL17064215 | 0.75 | SMN1; SMN2 (0.43) | LMNAKMT2ATP53RXFP1F2R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3113618-B1 | HETEROCYCLIC COMPOUNDS AS PEST CONTROLLERS | BAYER CROPSCIENCE AG (DE) | 2018-07-04 | — | — | EP | disclosed |
| US-9920017-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9920017-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-03-20 | — | — | US | disclosed |
| US-9920017-B2 | Heterocyclic compounds as pesticides | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2018-03-20 | — | — | US | disclosed |
| US-20170073318-A1 | HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073318-A1 | HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-03-16 | — | — | US | disclosed |
| US-20170073318-A1 | HETEROCYCLIC COMPOUNDS AS PESTICIDES | BAYER CROPSCIENCE AKTIENGESELLSCHAFT (DE) | 2017-03-16 | — | — | US | disclosed |
| EP-3113618-A1 | HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | Bayer CropScience Aktiengesellschaft (DE) | 2017-01-11 | — | — | EP | disclosed |
| WO-2015132313-A1 | HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2015-09-11 | — | — | WO | disclosed |
| WO-2015132313-A1 | HETEROCYCLIC COMPOUNDS AS PEST CONTROL AGENTS | BAYER CROPSCIENCE AG (DE) | 2015-09-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170073318-A1 | HETEROCYCLIC COMPOUNDS AS PESTICIDES | DDT, ACHE, PTMS | LMNA 1992/4885GAA 2156/4885KCNK3 2036/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.